Research programme: malaria vaccine - Etna
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Etna Biotech
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in Italy (Injection)
- 20 Mar 2014 Preclinical development is ongoing in Italy
- 27 Dec 2006 Preclinical trials in Malaria in Italy (Injection)